InWith Corp. Proposes EPGL Buyout Bid -> $EPGL Gains Third

New Post Public Reply Private Reply Replies (0) Message Board
Vikingzskillz
6,139
InWith Corp. Proposes EPGL Buyout Bid -> $EPGL Gains Third US Patent Allowance and InWith Corp. Proposes EPGL Buyout Bid
http://www.prnewswire.com/news-releases/epgl-...00030.html

Jan 31, 2017, 18:48 ET

IRVINE, Calif., Jan. 31, 2017 /PRNewswire/ -- EP Global Communications, Inc. (Public OTC: EPGL)

In a joint statement, EPGL announces that it has received its third consecutive US Patent allowance in the field of ophthalmic technologies while start-up partner InWith Corp. announces it will make a bid to buyout EPGL.



For EPGL, the allowed US Patent titled "Piezoelectric Sensor for Vision Correction" (U.S. 14/622,814), protects the sensing of the vibration of the ciliary muscle within the human eye, to trigger a self-focus mechanism within a soft contact lenses. EPGL's IP counsel was recently notified of the Allowance by the United States Patent and Trademark Office.

InWith Corp., a start-up company with plans to make new "body technologies" from wearable devices to implantable devices tied to a mobile wireless network, announced that it is seeking as much as $500 million in private funding.

InWith Corp. is a private company with 100 million authorized shares. InWith Corp. and EPGL previously announced a partnership to build EPGL's patented ophthalmic technologies. Several EPGL shareholders have requested and will receive a gift of Inwith Corp. equity. As a result, InWith Corp. will have private shareholders from all over the world. The Company has announced that Dr. Scott Peterson will be its Vice President. Dr. Peterson has been in practice for over 33 years and specializes in Glaucoma treatment and contact lenses. The management team of InWith Corp. will be fully announced by end of February 2017.

InWith Corp. will make a bid to buyout EP Global Communications, Inc. (EPGL) if EPGL shareholders allow the full offer to be presented by InWith Corp. via a Proxy Vote. The offer will involve a choice for EPGL's retail shareholders to be bought out in a cash price of up to 9.8 cents per share, or to receive approximately 125% of their current EPGL equity by percentage (total along with gifted shares) converted to InWith Corp. equity. The choice would be offered as "one or the other" to EPGL shareholders and they could make their choice individually from other shareholders. In any event, EPGL shareholders who formally requested the InWith Corp. gift equity offer, will receive that gift equity regardless if a full buyout is finalized.

EPGL will put the InWith Corp. detailed proposal before its shareholders in a Proxy Vote. The Company notes that other entities who hold first rights to purchase EPGL technologies, will continue to enjoy those rights through to the building of the products, regardless of any completed buyout.

About EP Global Communications, Inc.

EP Global Communications, Inc. is an advanced technology research and development company for both medical devices and consumer electronics devices specializing in microelectronic mechanical systems (MEMS).

For more information about EP Global Communications, Inc., visit www.epglmed.com

Email: investors@epglmed.com

About InWith Corporation

InWith Corporation is a privately manufacturer and brander of high technology products in the medical and consumer electronics field.

Email: info@inwithcorp.com

Website: www.inwithcorp.com





SOURCE EP Global Communications, Inc.

Related Links

http://www.epglmed.com





Jan 10, 2017, 14:57 ET

Preview: InWith Corp. to Build "InLens 1.0" Mobile Contact Lenses Using Patented EPGL Technology


Also from this source





Jan 10, 2017, 14:57 ET
InWith Corp. to Build "InLens 1.0" Mobile Contact Lenses Using...





Nov 03, 2016, 08:08 ET
EPGL Announces Partnership with New Technology Company Start-Up

EP Global Communications Inc. (EPGL) Stock Research Links

EPGL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring Advances in AI and Digital R&D Innovation by ICON plc

Updated Category News Views 227

Recent Developments in AI and Digital Innovation by ICON plc ICON plc, a globally recognized clinical research organization (NASDAQ: ICLR), has recently conducted an extensive survey exploring the integration of Artificial Intelligence (AI) and digital tools within clinical research. Engaging with over 100 professionals in the biotech and pharmaceutical industries across...

Continue Reading
Tesla's Self-Driving Claims Under Fire: Industry Reactions

Updated Category News Views 167

Tesla's License Suspension in California Recently, a court in California announced a significant development affecting Tesla Inc. (NASDAQ: TSLA). The court decided to suspend Tesla's license to sell vehicles for 30 days due to a lawsuit concerning misleading claims about the company's Full Self-Driving (FSD) technology. If Tesla does not adapt its policies within 90 days,...

Continue Reading
Sunnova Energy Faces Challenges Amid Revenue Declines in 2024

Updated Category News Views 384

Sunnova Energy Experiences Financial Struggles Sunnova Energy International Inc. (NOVA) has encountered a challenging period, with its shares trading lower in the premarket on Monday following a disappointing report detailing its fourth quarter and full-year financial results. The financial landscape for Sunnova shows a revenue of $224.127 million, which unfortunately...

Continue Reading
Kerusso's Important Contributions in Faith and Community Work

Updated Category News Views 133

Kerusso's Inspiring Charitable Contributions in 2025 Kerusso Activewear, a prominent Christian apparel and gift brand, has ended the year with a remarkable achievement of over $400,000 in charitable contributions. This reflects their steadfast commitment to enriching lives through faith-based approaches and generous support for individuals in need. Growing Demand for...

Continue Reading
Prelude Therapeutics and Incyte Join Forces for JAK2JH2 Inhibitor

Updated Category News Views 101

Prelude Therapeutics Partners with Incyte on JAK2V617F Program Incyte establishes exclusive option to acquire Prelude’s innovative programs These inhibitors have the potential to modify disease outcomes in patients with myeloproliferative neoplasms (MPNs) Prelude Therapeutics, a clinical-stage oncology company, has recently made headlines with an exciting announcement...

Continue Reading